Amgen wants to do everything that it can to protect its best-selling RA drug Enbrel from potential biosimilar competition, and now, the company is shoring up its defenses. Amgen is suing Novartis' Sandoz unit in federal court for infringing its Enbrel patents by developing a biosimilar version of the med.
The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.
F. Michael Ball, the former Hospira CEO who last month took over the top spot at Novartis' troubled Alcon unit, arrived with a lot on his plate. The division's sales are way off. It is shedding manufacturing and dealing with a recall in Japan. Now he can add to his list yet another product recall.
Novartis was all set to close the door on a Sandoz intermediates plant in Germany last year, thanks to some hefty competition from Asia. But now, the Swiss pharma giant has a buyer willing to take the plant--and salvage the 270 jobs that would have been chopped.
It was just 6 months ago that vaccines specialist CSL closed on its $275 million buyout of Novartis' influenza vaccines operations, getting three additional plants in the process. But the company says more capacity is needed and expansion is already underway in the U.K.
Novartis put a Sandoz intermediates plant in Germany on the chopping block last year, saying that Asian competition had eviscerated the market for its products. But the Swiss drugmaker has found a company willing to take the plant and save some of the hundreds of jobs that would have been lost.
Novartis is facing another regulatory pickle in Asia. After a Japanese data scandal forced the company's unit there into temporary suspension last year, South Korean prosecutors have targeted the company's Seoul-based unit with a kickbacks investigation.
Novartis picked up an FDA breakthrough therapy designation for its in-development treatment for blood cancer, guaranteeing the company preferred access to top regulators as it prepares to file for approval.
Changes are afoot at Novartis' struggling eyecare unit, where sales fell 13% to $2.3 billion during the previous quarter. Novartis CEO Joe Jimenez in January warned that Alcon has a "gap here that we're going to need to supplement."
Since acquiring Hospira, Pfizer's had a pair of Remicade biosimilars on its hands. Now, it's making moves to pare that number down to one, and Novartis will be reaping the benefits.